Oakworth Capital’s MacroGenics MGNX Stock Holding History

Oakworth Capital’s Portfolio MGNX Stock Details MGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-150	Closed	-$3K	–	652
2017 Q3	$3K	Buy	+150	New	+$2.6K	﹤0.01%	563

Other funds holding MGNX

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

IVM

InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Oakworth Capital's MGNX Position: Q4 2017 in Review

Oakworth Capital sold out of MacroGenics (MGNX) in Q4 2017, closing a stake of 150 shares — an estimated $3K sold.

Oakworth Capital first reported a position in MGNX in Q3 2017 and held it in 1 quarter. The position peaked at $3K in Q3 2017. 119 funds tracked by Wall St. Rank hold MGNX as of Q4 2017.

Oakworth Capital reported no remaining MacroGenics position as of Q4 2017 after selling out during the quarter.
Oakworth Capital sold 150 MacroGenics shares in Q4 2017, an estimated $3K.
Oakworth Capital first reported a position in MacroGenics in Q3 2017 and held it in 1 quarter.
Oakworth Capital's MacroGenics position peaked at $3K in Q3 2017.
119 funds tracked by Wall St. Rank held MacroGenics as of Q4 2017.

Based on Oakworth Capital's 13F filing for Q4 2017, filed 22 Jan 2018.